ThTxGNN: AI-Powered Drug Repurposing for Thailand NHI Drugs
Executive Summary
ThTxGNN is an open-source drug repurposing platform that leverages Harvard’s TxGNN deep learning model to predict potential new indications for Thailand National Health Insurance (NHI) approved drugs. Unlike prediction-only tools, ThTxGNN provides a complete evidence validation pipeline, integrating clinical trials, literature, and safety data to generate actionable reports.
Key Differentiators
Feature
Description
Evidence-Based Predictions
Every prediction is validated against ClinicalTrials.gov, PubMed, and other authoritative sources
Five-Level Evidence Classification
L1 (multiple Phase 3 RCTs) to L5 (AI prediction only)
SMART on FHIR Integration
Ready-to-use app for EHR integration
FHIR R4 API
Static FHIR resources for external system integration
Comprehensive Safety Data
222,391 DDI records, 8,359 DDSI records
Data Overview
Metric
Count
Drug Reports
191
Drug Repurposing Candidates
142,328
Predicted Indications
1,268
Drug-Drug Interactions (DDI)
222,391
Drug-Disease Contraindications (DDSI)
8,359
Evidence Distribution
Level
Definition
Drug Count
L1
Multiple Phase 3 RCTs
6
L2
Single RCT or Phase 2 trials
12
L3
Observational studies
16
L4
Preclinical / mechanistic
19
L5
AI prediction only
138
Technology Stack
Prediction Model
TxGNN: Published in Nature Medicine (2023) by Harvard Zitnik Lab
Method: Knowledge graph + deep learning for drug-disease relationship prediction
This platform is intended for research purposes only and does not constitute medical advice. All drug repurposing predictions require clinical validation before application. Healthcare decisions should be made in consultation with qualified medical professionals.